{"transactions":[{"id":910166,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-02-11T21:00:15.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":false,"shares":203851,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 9, 2027, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive."}],"balance_after":203851,"derivative":{"exercise_price":13.48,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":203851},"source":{"system":"sec-edgar","filing":"0001193125-26-047316","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312526047316/ownership.xml","form_type":"4"}},{"id":971448,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-12T20:30:02.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":7000,"price":14.485,"value":101395.0,"ownership":{"direct":true},"balance_after":1551613,"source":{"system":"sec-edgar","filing":"0001193125-25-318069","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525318069/ownership.xml","form_type":"4"}},{"id":1017689,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-10-16T18:14:38.000Z","date":"2025-10-15","kind":"exercise","planned":false,"acquired":false,"shares":1229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive."}],"balance_after":40566,"derivative":{"exercise_price":4.24,"expiration_date":"2034-07-20","underlying":"Common Stock","underlying_shares":1229},"source":{"system":"sec-edgar","filing":"0001193125-25-241647","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525241647/ownership.xml","form_type":"4"}},{"id":1017688,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T18:14:38.000Z","date":"2025-10-15","kind":"exercise","planned":false,"acquired":true,"shares":1229,"price":4.24,"value":5210.96,"ownership":{"direct":true},"balance_after":1544613,"source":{"system":"sec-edgar","filing":"0001193125-25-241647","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525241647/ownership.xml","form_type":"4"}},{"id":1039497,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-16T06:15:03.000Z","date":"2025-09-15","kind":"purchase","planned":false,"acquired":true,"shares":3500,"price":9.9442,"value":34804.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.93 to $9.9798 per share, inclusive. The reporting person undertakes to provide Aardvark, any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":1543384,"source":{"system":"sec-edgar","filing":"0001193125-25-204233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525204233/ownership.xml","form_type":"4"}},{"id":1039496,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-16T06:15:03.000Z","date":"2025-09-15","kind":"purchase","planned":false,"acquired":true,"shares":6500,"price":9.5106,"value":61818.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.9045 to $9.89 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. (\"Aardvark\"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":1539884,"source":{"system":"sec-edgar","filing":"0001193125-25-204233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525204233/ownership.xml","form_type":"4"}},{"id":1041743,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-12T20:28:02.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":8.5031,"value":42515.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.4199 to $8.69 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. (\"Aardvark\"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":1533384,"source":{"system":"sec-edgar","filing":"0001193125-25-202490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525202490/ownership.xml","form_type":"4"}},{"id":1041742,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-12T20:28:02.000Z","date":"2025-09-11","kind":"purchase","planned":false,"acquired":true,"shares":6000,"price":7.821,"value":46926.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.8135 to $7.825 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. (\"Aardvark\"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":1528384,"source":{"system":"sec-edgar","filing":"0001193125-25-202490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525202490/ownership.xml","form_type":"4"}},{"id":1041741,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-12T20:28:02.000Z","date":"2025-09-10","kind":"purchase","planned":false,"acquired":true,"shares":9000,"price":7.9125,"value":71212.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.84 to $7.95 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. (\"Aardvark\"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":1522384,"source":{"system":"sec-edgar","filing":"0001193125-25-202490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525202490/ownership.xml","form_type":"4"}},{"id":1053012,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-08-29T16:05:05.000Z","date":"2025-08-28","kind":"exercise","planned":false,"acquired":false,"shares":17209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive."}],"balance_after":41795,"derivative":{"exercise_price":4.24,"expiration_date":"2034-07-20","underlying":"Common Stock","underlying_shares":17209},"source":{"system":"sec-edgar","filing":"0001193125-25-192747","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525192747/ownership.xml","form_type":"4"}},{"id":1053011,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-29T16:05:05.000Z","date":"2025-08-28","kind":"exercise","planned":false,"acquired":true,"shares":17209,"price":4.24,"value":72966.16,"ownership":{"direct":true},"balance_after":1513384,"source":{"system":"sec-edgar","filing":"0001193125-25-192747","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000119312525192747/ownership.xml","form_type":"4"}},{"id":1112041,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-06-13T16:05:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":549534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on June 11, 2026, and 1/48th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive."}],"balance_after":549534,"derivative":{"exercise_price":11.29,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":549534},"source":{"system":"sec-edgar","filing":"0000950170-25-086147","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000095017025086147/ownership.xml","form_type":"4"}},{"id":1260535,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-19T16:35:58.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":false,"shares":350002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41303},"source":{"system":"sec-edgar","filing":"0000950170-25-023253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000095017025023253/ownership.xml","form_type":"4"}},{"id":1260534,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-19T16:35:58.000Z","date":"2025-02-14","kind":"purchase","planned":false,"acquired":true,"shares":16542,"price":16,"value":264672.0,"ownership":{"direct":true},"balance_after":1496175,"source":{"system":"sec-edgar","filing":"0000950170-25-023253","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000095017025023253/ownership.xml","form_type":"4"}},{"id":1260533,"issuer":{"id":6598,"kind":"organization","name":"Aardvark Therapeutics, Inc.","symbol":"AARD"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-19T16:35:58.000Z","date":"2025-02-14","kind":"exercise","planned":false,"acquired":true,"shares":41303,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the \"Issuer\") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date."}],"balance_after":1479633,"source":{"system":"sec-edgar","filing":"0000950170-25-023253","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000095017025023253/ownership.xml","form_type":"4"}},{"id":2053908,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":66911,"kind":"person","name":"Lee Tien-Li","position":1,"cik":"0001940120","reported_name":"Lee Tien-Li","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2023-01-17T17:31:54.000Z","date":"2023-01-17","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":8.08,"expiration_date":"2033-01-17","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-23-001880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940120/000089924323001880/doc4.xml","form_type":"4"}}]}